Menu

Sensory Experience Shapes a Growing Brain:Regulation of Sensory-Dependent Circuit Refinement by TWEAK/Fn14 Cytokine Signaling

Advanced Cell Diagnostics invites you to join them for an educational webinar on the topic of sensory-dependent circuit refinement in the brain.

Nov 27, 2018
The Scientist Creative Services Team


FREE Webinar

Tuesday, January 22, 2019
2:30-4:00 PM Eastern Time
Register Now

Sensory experience sculpts neural connectivity via cellular and molecular mechanisms that are still largely unknown. Through a combination of single-cell transcriptomics, structural analysis, and electrophysiology, Dr. Lucas Cheadle and colleagues identified the secreted cytokine TWEAK and its receptor Fn14 as important regulators of sensory-dependent synaptic remodeling. Hear from Cheadle about his use of multiplexed mRNA detection in situ with spatial resolution to reveal temporally coordinated, experience-dependent expression of TWEAK in microglia and Fn14 in excitatory neurons, suggesting that experience regulates circuit development by initiating complementary transcriptional programs in neuronal and non-neuronal cells. This webinar is sponsored by Advanced Cell Diagnostics.

Topics to be covered:

  • Single-cell transcriptomics and in situ validation of sensory-driven gene expression
  • Sensory experience-dependent refinement of neural circuits by transcriptional control in activated neurons
  • Induction of TWEAK expression in microglia by sensory stimulation

Register Now

Meet the Speakers:

Lucas M. Cheadle, PhD
Postdoctoral Fellow (Greenberg Lab)
Department of Neurobiology
Harvard Medical School


Courtney Anderson, PhD
Research Manager, Applications
Advanced Cell Diagnostics


March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.
Advanced Chromatography Preparation and Separation Solutions Deliver Robust and Reliable Sample Analysis
Advanced Chromatography Preparation and Separation Solutions Deliver Robust and Reliable Sample Analysis
New sample preparation workflow and chromatography column enable rapid and reproducible characterization of steroid hormones and sensitive separation of drugs of abuse
Sartorius Introduces Cubis® II Modular Laboratory Balances for Improved Operational Efficiency and Unmatched Flexibility
Sartorius Introduces Cubis® II Modular Laboratory Balances for Improved Operational Efficiency and Unmatched Flexibility
- Fully customizable enabling thousands of configurations optimized for the user’s workflow- Supports 21 CFR part 11 and EU Annex 11 compliance with complete traceability- Easy, seamless integration with existing lab software and LIMS